Search

Author/Creator Lai, Eseng

1. 1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects. (26th November 2018)

Authors:
Aliprantis, Antonios; Wolford, Dennis; Caro, Luzelena; Maas, Brian; Ma, Hua; Vora, Kalpit; Geng, Dong; Railkar, Radha; Lee, Andrew; Sterling, Laura; Lai, Eseng
Journal:
Open forum infectious diseases
Issue:
Volume 5(2018)Supplement 1
Page Start:
S572
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults. Issue 5 (30th October 2020)

Authors:
Aliprantis, Antonios O.; Wolford, Dennis; Caro, Luzelena; Maas, Brian M.; Ma, Hua; Montgomery, Diana L.; Sterling, Laura M.; Hunt, Allen; Cox, Kara S.; Vora, Kalpit A.; Roadcap, Brad A.; Railkar, Radha A.; Lee, Andrew W.; Stoch, S. Aubrey; Lai, Eseng
Journal:
Clinical pharmacology in drug development
Issue:
Volume 10:Issue 5(2021)
Page Start:
556
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Issue 5 (4th May 2021)

Authors:
Aliprantis, Antonios O.; Shaw, Christine A.; Griffin, Paul; Farinola, Nicholas; Railkar, Radha A.; Cao, Xin; Liu, Wen; Sachs, Jeffrey R.; Swenson, Christine J.; Lee, Heather; Cox, Kara S.; Spellman, Daniel S.; Winstead, Colleen J.; Smolenov, Igor; Lai, Eseng; Zaks, Tal; Espeseth, Amy S.; Panther,...
Journal:
Human vaccines & immunotherapeutics
Issue:
Volume 17:Issue 5(2021)
Page Start:
1248
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment. Issue 6 (27th April 2017)

Authors:
Chacra, Antonio; Gantz, Ira; Mendizabal, Geraldine; Durlach, Lucila; O'Neill, Edward A.; Zimmer, Zachary; Suryawanshi, Shailaja; Engel, Samuel S.; Lai, Eseng
Journal:
International journal of clinical practice
Issue:
Volume 71:Issue 6(2017)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. (3rd October 2017)

Authors:
Shankar, R. Ravi; Inzucchi, Silvio E.; Scarabello, Victoria; Gantz, Ira; Kaufman, Keith D.; Lai, Eseng; Ceesay, Paulette; Suryawanshi, Shailaja; Engel, Samuel S.
Journal:
Current medical research and opinion
Issue:
Volume 33:Number 10(2017)
Page Start:
1853
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. (April 2018)

Authors:
Home, Philip; Shankar, R. Ravi; Gantz, Ira; Iredale, Carol; O'Neill, Edward A.; Jain, Lokesh; Pong, Annpey; Suryawanshi, Shailaja; Engel, Samuel S.; Kaufman, Keith D.; Lai, Eseng
Journal:
Diabetes research and clinical practice
Issue:
Volume 138(2018)
Page Start:
253
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. (3rd October 2017)

Authors:
Handelsman, Yehuda; Lauring, Brett; Gantz, Ira; Iredale, Carol; O'Neill, Edward A.; Wei, Ziwen; Suryawanshi, Shailaja; Kaufman, Keith D.; Engel, Samuel S.; Lai, Eseng
Journal:
Current medical research and opinion
Issue:
Volume 33:Number 10(2017)
Page Start:
1861
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes. Issue 11 (6th July 2017)

Authors:
Gantz, Ira; Okamoto, Taro; Ito, Yuka; Okuyama, Kotoba; O'Neill, Edward A.; Kaufman, Keith D.; Engel, Samuel S.; Lai, Eseng
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 19:Issue 11(2017)
Page Start:
1602
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. (6th June 2014)

Authors:
Lauring, Brett; Li, Xiujiang (Susie); Liu, Yang; Corr, Christy; Lazarus, Nicole; Cote, Josee; Larson, Patrick; Levonas, Amy O. Johnson; Lasseter, Kenneth C.; Preston, Richard A.; Smith, William B.; Lai, Eseng; Wagner, John A.
Journal:
Journal of clinical pharmacology
Issue:
Volume 54:Number 11(2014:Nov.)
Page Start:
1247
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗